Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432668 | 0.90 | HDAC1 (0.46) | PLAUTRPV1ALOX5MRGPRX4PTPN1 | |
| SCHEMBL1963401 | 0.86 | MTNR1A (0.50) | PLAUTRPV1NPC1RAB9A | |
| SCHEMBL14134840 | 0.84 | MTNR1A (0.51) | PLAUTRPV1 | |
| SCHEMBL7936792 | 0.83 | KLK5 (0.50) | PTPN1HDAC1 | |
| SCHEMBL3910099 | 0.82 | MAOB (0.53) | PTPN1HDAC1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL629633 | 0.82 | ALOX5 (0.47) | ALOX5MRGPRX4PTPN1HDAC1SMN1; SMN2 | |
| SCHEMBL14433303 | 0.82 | TRPV1 (0.53) | PLAUTRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20597195 | 0.82 | NQO2 (0.46) | PLAUALOX5MRGPRX4PTPN1HDAC1 | |
| SCHEMBL7381558 | 0.81 | CTSV (0.52) | HDAC1SMN1; SMN2NPC1RAB9APDK1 | |
| SCHEMBL22626751 | 0.81 | NPC1 (0.50) | HDAC1SMN1; SMN2NPC1RAB9APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | disclosed |
| EP-1670780-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-21 | — | — | EP | disclosed |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-09-22 | — | — | US | disclosed |
| WO-2005030151-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1090011-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6441017-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-6410534-B1 | ANTICANCER AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1214326-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1090011-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001018006-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000001701-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | PDGFRA, RAF1, FLT1 | PLAU 3885/4885TRPV1 2192/4885ALOX5 3539/4885 |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | LCK, RAF1, MAP3K1 | PLAU 3662/4885TRPV1 2865/4885ALOX5 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.